DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

Information source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcoholism

Intervention: ondansetron (Zofran) (Drug); naltrexone (ReVia) (Drug); Cognitive Behavioral Therapy (Behavioral)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Summary

This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.

Clinical Details

Study design: Treatment, Randomized, Double-Blind, Placebo Control

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Current diagnosis of alcohol dependence.

- Provide a written informed consent.

- Must weigh within 30% of their ideal body weight.

- Patients must weigh at least 89 lbs. and no more than 342 lbs.

- Good physical health.

- Currently drinking 14 or more alcohol units per week for women and 21 or more alcohol

units per week for men in the last 30 days.

- Provide evidence of stable residence in the last month prior to enrollment in the

study.

- No plans to move in the nine months after entering the study.

- Literate in English and able to read, understand, and complete questionnaires and

follow instructions.

- Willingness to participate in behavioral treatment for alcoholism.

Exclusion Criteria:

- Current psychiatric disorder other than alcohol or nicotine dependence.

- Elevated liver enzymes or elevated bilirubin.

- Severe alcohol withdrawal symptoms which require treatment.

- Serious medical co-morbidity requiring medical intervention or close supervision.

- Severe or life-threatening adverse reactions to medications in the past or during this

trial.

- Female patients who are pregnant, lactating, or not adhering to an acceptable form of

contraception at any time during the study.

- Received inpatient or outpatient treatment for alcohol dependence within the last 30

days.

- Compelled to participate in an alcohol treatment program for alcohol dependence to

maintain their liberty.

- Members of the same household.

- Tuberculosis.

- Current treatment with any medications having a potential effect on alcohol

consumption and related behaviors or mood.

- Urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines,

prescription and non-prescription drugs.

- Pyrexia of unknown origin.

Locations and Contacts

University of Texas Health Science Center, San Antonio, Texas 78229, United States
Additional Information

Starting date: September 2001
Ending date: August 2004
Last updated: December 7, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014